Home » Business, Health & Medicine, News & Current Affairs, Pharmaceuticals & Biotech » Generic Drugs Market Review & Forecasts to 2016-2021 – Industry Analysis by Drivers and Restraints, Mergers and Acquisition, Government Policies and Strategies and Top Companies
“Market Research Reports and Industry Analysis”
OrbisResearch.com has published “The Future of Generic Drugs and Strategies for Commercial Success” market report to its research database. The top global generic drug companies by revenue are also examined, including financial performance and recent activity within the market. Companies listed in the report are Teva, Sandoz, Mylan, Sun Pharma, Aspen, Hospira, Fresenius Kabi, and Lupin.

GBI Research’s latest report “The Future of Generic Drugs and Strategies for Commercial Success” discusses trends in the global generic drugs market, and the evolving business strategies being adopted and leveraged by generic drug companies around the world. GBI Research conducted an extensive and targeted industry survey of experts from top global generic drug companies, to gather opinions on the trends and future commercial prospects of the generic drugs market. The findings from the survey and results from extensive data analysis and secondary research efforts have been triangulated with GBI’s own analytical views to provide an objective assessment that is comprehensive in outlook.

The generic drugs market has seen rapid expansion for more than 30 years, and consistently achieves higher annual growth rates than the overall pharmaceutical market. The increase in generic drug activity can be primarily attributed to the promise of significant revenues from blockbuster drugs nearing patent expiry. In the US – the largest generic drugs market by revenue – the number of generic drug approvals hit a record high in 2015, due to a new program that aimed to speed up approvals. There has also recently been a surge in the number of industry-transforming mergers and acquisitions, with companies looking to consolidate their position in this highly lucrative market.

The results of GBI’s latest industry survey provide insightful analyses from different expert panels, including R&D and commercial, and highlight trends observed in key geographical markets. The survey examined key commercial issues and recent developments in the generic drugs market, such as the reasons behind the surge in mergers and acquisitions, and the likely effects on market dynamics. It covered important factors currently driving or restraining the market, prospects for key therapy areas expected to exhibit significant levels of genericization in the coming years, and the most promising emerging markets for generic companies in terms of revenue potential. Additionally, the survey examined common business strategies and regulations being leveraged by global generic drug companies for market expansion.

Request a sample of this report at http://www.orbisresearch.com/contacts/request-sample/137765 .

The report covers key small molecule drugs whose patents will expire in the coming years, providing an in-depth assessment of potential generic competition, expected launch dates and the overall impact on global branded revenues to 2021. The top global generic drug companies by revenue are also examined, including financial performance and recent activity within the market.

This new report adds to our unique portfolio of trusted industry analyses, which enable our clients to assess the most promising commercial areas in the market and identify key business opportunities.

Scope
– What is the current value of the generic drugs market, and how will market dynamics change in the coming years?
– Will the US continue to dominate the market?
– Which therapy areas will witness the highest level of genericization in the next five years?

Drivers and restraints in the generics industry:
– What are the most important factors promoting generic drug usage at a global level?
– What are the most important factors hindering or delaying generic drug approvals?
– Will governments worldwide continue their efforts to promote generic drug usage?
– How will global demographic trends impact demand for generic drugs?
– Which emerging economies are the most promising for generic drugs companies?
– Are generic drugs still negatively perceived?
– How are pricing pressures and rising costs affecting generic drug manufacturers?

Generic drugs pipeline for top small molecule drugs in the market:
– What will be the revenue impact for key small molecule drugs whose patents expire in the near future?
– What are the key patent expiry dates for these small molecules and what level of generic competition should they expect?

Strategies for commercial success:
– What are the most popular strategies or regulations being adopted and leveraged by generic drug manufacturers?
– What governmental policies are significantly influencing generic drug usage?
– What will be the impact of compulsory licenses in emerging markets?

Top global generic drugs companies:
– How have top generic drugs companies performed in recent years?
– What are the prospects for top generic drugs companies?

Place a direct purchase order on this report at http://www.orbisresearch.com/contact/purchase/137765 . AND if you have enquire before buying this report visit at http://www.orbisresearch.com/contacts/enquiry-before-buying/137765 .

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Media Contact
Company Name: Orbis Research
Contact Person: Hector Costello
Email: sales@orbisresearch.com
Phone: +1 (214) 884-6817
Address:4144N Central Expressway, Suite 600
City: Dallas
State: Texas
Country: United States
Website: http://www.orbisresearch.com/publisher/cbr-pharma-insights.html

Comments are closed.